Eli Lilly and Company

Grant Mathews Vaught

William Joseph Hornback

Cynthia Darshini Jesudason

Richard Todd Pickard

Robert Alan Gadski

Lisa Selsam Beavers

Philip Arthur Hipskind

Brian Morgan Watson

Don Richard Finley

Takako Takakuwa

Terry Patrick Finn

Charles Willis Lugar, Iii

Dustin James Mergott

Ryan Edward Stites

Freddie Craig Stevens

Serge Louis Boulet

Timothy Ivo Richardson

John Richard Morphy

Chongsheng Eric Shi

Selma Sapmaz

Christian Alexander Clarke

Helene Rudyk

Leonard Larry Winneroski

Charles Willis Lugar Iii

Terry Patrick Eli Lilly And Company Finn

The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A). 

Compounds useful for inhibiting ROR&#x3b3;t

The present invention provides BACE inhibitors of Formula I: methods for their use, intermediates, and methods for their preparation.

BACE inhibitors

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I). 

Histamine H3 receptor agents, preparation and therapeutic uses

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine&#x2014;H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor&#x2014;related diseases 

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently &#x2014;(C&#x2014;C) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence &#x2014;H, -halogen, or &#x2014;CH. 

Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

Growing community of inventors

Indianapolis, IN, United States of America

Grant Mathews Vaught